标题
Glatiramer Acetate in the Treatment of Multiple Sclerosis
作者
关键词
-
出版物
CNS DRUGS
Volume 25, Issue 5, Pages 401-414
出版商
Springer Nature
发表日期
2011-03-30
DOI
10.2165/11588120-000000000-00000
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity
- (2010) Martin S. Weber et al. ANNALS OF NEUROLOGY
- Increased expression of B cell-associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis
- (2010) Sakhina Begum-Haque et al. JOURNAL OF NEUROIMMUNOLOGY
- Long-term treatment of multiple sclerosis with glatiramer acetate: Natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy
- (2010) Dimitros Karussis et al. JOURNAL OF NEUROIMMUNOLOGY
- Glatiramer acetate triggers PI3Kδ/Akt and MEK/ERK pathways to induce IL-1 receptor antagonist in human monocytes
- (2010) Rakel Carpintero et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?
- (2009) Amit Bar-Or et al. ANNALS OF NEUROLOGY
- B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis
- (2009) Mrinalini Kala et al. EXPERIMENTAL NEUROLOGY
- Long-Term Study of Brain1H-MRS Study in Multiple Sclerosis: Effect of Glatiramer Acetate Therapy on Axonal Metabolic Function and Feasibility of Long-Term1H-MRS Monitoring in Multiple Sclerosis
- (2009) Omar Khan et al. JOURNAL OF NEUROIMAGING
- 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
- (2009) Paul O'Connor et al. LANCET NEUROLOGY
- Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate
- (2009) V. Skihar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1 in human monocytes and multiple sclerosis
- (2009) D. Burger et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Exacerbation of autoimmune arthritis by copolymer-I through promoting type 1 immune response and autoantibody production
- (2008) Biao Zheng et al. AUTOIMMUNITY
- Regulatory B cells as inhibitors of immune responses and inflammation
- (2008) Jean-David Bouaziz et al. IMMUNOLOGICAL REVIEWS
- Glatiramer acetate: A novel therapeutic approach in Crohnʼs disease?
- (2008) Albrecht Neesse et al. INFLAMMATORY BOWEL DISEASES
- Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model
- (2008) P. Borel et al. INTERNATIONAL IMMUNOLOGY
- Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
- (2008) Daniel D Mikol et al. LANCET NEUROLOGY
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis
- (2008) R. Aharoni et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells
- (2008) T. Korn et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started